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Abstract: The severe inflammation observed during sepsis is thought to cause diaphragm 
dysfunction, which is associated with poor patient prognosis. Cerium oxide (CeO
2
) nanopar-
ticles have been posited to exhibit anti-inflammatory and antioxidative activities suggesting 
that these particles may be of potential use for the treatment of inflammatory disorders. To 
investigate this possibility, Sprague Dawley rats were randomly assigned to the following 
groups: sham control, CeO
2
 nanoparticle treatment only (0.5 mg/kg iv), sepsis, and sepsis+CeO
2
 
nanoparticles. Sepsis was induced by the introduction of cecal material (600 mg/kg) directly 
into the peritoneal cavity. Nanoparticle treatment decreased sepsis-associated impairments in 
diaphragmatic contractile (P
o
) function (sham: 25.6±1.6 N/cm2 vs CeO
2
: 23.4±0.8 N/cm2, vs Sep: 
15.9±1.0 N/cm2 vs Sep+CeO
2
: 20.0±1.0 N/cm2, P,0.05). These improvements in diaphragm 
contractile function were accompanied by a normalization of protein translation signaling (Akt, 
FOXO-1, and 4EBP1), diminished proteolysis (caspase 8 and ubiquitin levels), and decreased 
inflammatory signaling (Stat3 and iNOS). Histological analysis suggested that nanoparticle 
treatment was associated with diminished sarcolemma damage and diminished inflammatory 
cell infiltration. These data indicate CeO
2
 nanoparticles may improve diaphragmatic function 
in the septic laboratory rat.
Keywords: cerium oxide nanoparticles, anti-inflammatory, nitric oxide, diaphragm
Introduction
The pharmacological application of nanotechnology has become an area of intense 
interest in recent years, and some have posited that cerium oxide (CeO
2
) nanoparticles 
may be uniquely suited for several different types of biomedical applications.1 Ceria 
is an element of the lanthanide series that when complexed with oxygen allows it to 
effectively transition between oxidative states (Ce+3 and Ce+4) where it can participate 
in redox cycling and function as antioxidant.2 Other data have suggested that CeO
2
 
nanoparticles are thought to be largely nontoxic under physiologic conditions,3 that 
they appear to be well tolerated in vivo,4 that may also exhibit antimicrobial effects,5 
and that they may be useful for the treatment of disease states characterized by eleva-
tions in cellular reactive oxygen species.6 Consistent with these data, recent studies 
have demonstrated that CeO
2
 nanoparticles may be useful for the treatment of condi-
tions associated with elevated oxidative stress including cardiac dysfunction, some 
types of neurodegeneration, cancer, and inflammation.7–10 Despite numerous medical 
advancements, the mortality rate associated with sepsis-associated multiple organ 
dysfunction syndrome remains unacceptably high as it is the leading cause of death in 
the hospital intensive care unit.11 Sepsis and other severe inflammatory disorders are 
often associated with diaphragm dysfunction, which if uncorrected oftentimes results 
in decreased survivability and the need for ventilator support.12–14
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Recent work by our laboratory has suggested that treatment 
with CeO
2
 nanoparticles is associated with diminished sepsis-
induced mortality and decreased levels of systemic inflam-
mation after polymicrobial insult.15 Whether this increase in 
survivability following CeO
2
 nanoparticle intervention also 
associated with improvements of diaphragm function is cur-
rently unclear. On the basis of previous data demonstrating 
that rodent diaphragm is particularly susceptible to eleva-
tions in oxidative stress and circulating cytokines,16–18 we 
hypothesized that septic animals that had been treated with 
CeO
2
 nanoparticles would exhibit improved diaphragmatic 
function compared with that observed in the untreated coun-
terparts. Our findings suggest that CeO
2
 nanoparticle treat-
ment improves diaphragm contractility following a severe 
polymicrobial insult, and that this finding is associated with 
evidence of diminished muscle damage and inflammation.
Materials and methods
Materials
All chemicals were purchased from Sigma-Aldrich Co. 
(St Louis, MO, USA), unless otherwise specifically stated. 
Antibodies against Phospho-Akt (Ser473) (C31E5E)(#4060), 
Akt (pan) (40D4) (#2920), Phospho-Stat3 (Tyr705) (D3A7) XP 
(#9145), Stat3 (#9132), α-tubulin (#2144), Bax (#2772), Bcl-2 
(#2876), Ubiquitin (p4D1) (#3936), 4E-BP1 phos(thr37/46) 
(#9459), and 4E-BP1 Non phos (thr46) (#4923) were pur-
chased from Cell Signaling Technology (Beverly, MA, USA). 
Horseradish peroxidase-conjugated anti-mouse (#7076) and 
anti-rabbit (#7074) secondary antibodies were also purchased 
from Cell Signaling Technology. Caspase 8 primary antibody 
(sc-7890) was obtained from Santa Cruz Biotechnology Inc. 
(Dallas, TX, USA). iNOS primary antibody (PA1-036) was 
from Pierce (Rockford, IL, USA).
animals
Ten-week-old male Sprague Dawley rats were purchased 
from Hilltop Laboratories (Scottdale, PA, USA) and housed 
for 1–2 weeks to allow acclimation before the initiation of 
any experiments. Animals were housed two to a cage with 
12–12 dark–light cycles at 25°C. Food and water were 
provided ad libitum. All animal care and experimental 
procedures were performed after approval by the Marshall 
University Institutional Animal Care and Use Committee, 
and in accordance with the Guide for the Care and Use of 
Laboratory Animals.19
Cecal inoculum peritonitis model
Animals were anesthetized using isoflurane and fecal peri-
tonitis was induced by making a small abdominal incision 
followed by the introduction of cecal material and closure 
of the incision as described previously.20 The cecal material 
was prepared by mixing cecal contents obtained from fresh 
donor rats with 5% dextrose water to yield a concentration 
of 600 mg cecal material in 5 mL/kg. The cecal material was 
used immediately and prepared fresh for each experiment. 
The cecal inoculums (CI) and CI+CeO
2
 nanoparticle treat-
ment animals received fresh inoculum from the same donor 
animal for each experiment. Sham control and CeO
2
-only ani-
mals underwent an identical surgery to induce fecal peritonitis 
but received sterile dextrose water (5 mL/kg, ip) only.
CeO2 nanoparticle treatment
The characterization of CeO
2
 nanoparticles (US Research 
Nanomaterials, Inc., Houston, TX, USA) were imaged using 
a JEOL JEM-2010 (JEOL, Tokyo, Japan) transmission 
electron microscope as previously described.21,22 Scanning 
transmission electron microscopy images were acquired 
using an aberration-corrected analytical electron microscope 
(transmission electron microscope [TEM]/scanning transmis-
sion electron microscope [STEM] JEOL JEM-ARM200CF) 
operated at 200 keV.
For the nanoparticle treatment groups, CeO
2
 nanoparticles 
(0.5 mg/kg) in 200 µL of sterile distilled water were given 
via the tail vein at the time of peritonitis induction or sham 
surgery. This dose was chosen based on our preliminary 
data from pilot studies examining animal mortality and 
previously published data.15,21 The sham control and the CI 
groups received vehicle (200 µL of sterile distilled water). 
For the biochemical assessments, animals were sacrificed 
at 3 or 18 hours while functional assessments of diaphragm 
contractility were performed at 18 hours. These time points 
were selected based on previous data suggesting that the 
3-hour time point appears to represent the initial systemic 
inflammatory response syndrome phase while the 18-hour 
time point coincides with the development of multiple organ 
dysfunction.15
In vitro diaphragm contraction
Diaphragm contractile function was measured as previously 
described.23,24 Briefly, the entire diaphragm with ribs and the 
central tendon attached was removed from isoflurane anes-
thetized animals and quickly placed in ice cold Krebs buffer 
solution containing (mM) 118 NaCl, 4.7 KCl, 2.5 CaCl
2
, 
1.2 MgSO
4
, 10 glucose, 1.2 NaH
2
PO
4
, and 25 NaHCO
3
 oxy-
genated with 95% O
2
 plus 5% CO
2
 to maintain pH 7.4. Two 
rectangular muscle strips approximately 3–4 mm in width 
from the costal region of each hemidiaphragm were dissected 
from the central tendon to the rib along the fiber orientation. 
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The central tendon and ribs were tied with silk sutures with 
loops to mount the muscle strips in the organ bath. The 
muscle strips were mounted on the two stainless pins in a 
glass organ bath, and electrical field stimulation (EFS) was 
delivered using two platinum electrodes along either side of 
the muscle (Grass Stimulator S88). The Krebs buffer solution 
in the organ bath contained 10 µM d-tubocurarine chloride 
(Sigma-Aldrich Co.) to block nicotinic acetylcholine recep-
tors during electric stimulations, and the bath temperature 
was kept at 25°C. After the 15-minute equilibration, EFS 
with 2 milliseconds single square-wave pulse was delivered 
at super maximal voltage set at 140 V to contract the muscle 
strips. To determine optimal tension (L
o
), diaphragm muscle 
strips were stretched in a stepwise manner, and the single-
pulse twitch protocol was repeated to achieve the maximum 
active tension. Thereafter, tetanic tension was assessed at 
L
o
 by measuring active tension developed in response to the 
sequential stimulation with trains of 1–150 Hz stimuli (train 
duration 500 milliseconds). An interval of 3 minutes was 
used between the muscle contractions. Isometric contraction 
was recorded using a force displacement transducer (Grass 
Technologies, Warwick, RI) interfaced with a Grass poly-
graph, and the data were digitized at 5 kHz using a storage 
oscilloscope (DSO-8502, Link Instrument Inc., Fairfield, 
NJ, USA). Specific tension was normalized to the estimated 
muscle cross-sectional area by the following equation:
 Cross sectional area = wet weight (g)/length (cm)  
  ×1.06 (density g/cm3).25
Immunoblot analysis
Semiquantitiative immunodetection was performed as 
detailed previously.26 Briefly, diaphragms were pulver-
ized and then homogenized in Tissue Protein Extraction 
Reagent (Pierce) supplemented with 1 mM Dithiothreitol 
(DTT), protease, and phosphatase inhibitor cocktails 
(Sigma-Aldrich Co.). Lysates were sonicated on ice and 
centrifuged at 10,000× g at 4°C for 10 minutes. The 
supernatant was removed, and protein concentration was 
determined by 660 protein assay reagent (Thermo Fisher 
Scientific, Waltham, MA, USA). Samples were diluted in 
Laemmli sample buffer, and equal amounts of protein were 
separated by SDS-PAGE, followed by electroblotting onto 
nitrocellulose membranes. Membranes were blocked with 
5% milk in Tris Buffered Saline with Tween (TBST) for 
1 hour at room temperature and washed three times in TBST 
before incubation overnight at 4°C with primary antibodies. 
Membranes were incubated with the secondary antibody 
conjugated with horseradish peroxidase (HRP) for 1 hour at 
room temperature. An enhanced chemiluminescence (ECL) 
was used to detect immunoreactivity using a FluorChem E 
System (Cell Biosciences, Santa Clara, CA, USA).
Histochemical analysis
Procion orange
A bolus administration of 1.5 mL (3% Procion orange in 0.9% 
sterile saline) was infused via femoral vein catheter. After 
allowing the dye to circulate for 15 minutes, the diaphragm 
muscle was removed and quickly frozen in liquid nitrogen-
cooled isopentane.27 In some animals, muscle strips were 
immersed in HEPES buffer containing 0.2% Procion orange 
(Sigma-Aldrich Co.) for 1 hour at room temperature and 
quickly frozen as described above.28 Frozen tissues were 
serially sectioned in 10 µm and placed on poly-lysine-coated 
slides before imaging with an inverted fluorescent microscope 
(EVOS AMG, Bothell, WA, USA) under a green fluorescent 
protein filter (excitation 450 nm/emission 505 nm).
hematoxylin and eosin staining
Frozen tissue sections from animals without Procion orange 
perfusion were fixed in 4% formalin in phosphate buffer 
solution (PBS), and the sections were stained with H&E 
according to the manufacturer (BBC Biochemical, Mount 
Vernon, WA, USA). Images were obtained using an inverted 
microscope (EVOS AMG).
real-time polymerase chain reaction
Real-time polymerase chain reaction (PCR) was performed for 
quantification of iNOS and GAPDH using a 7500 Real Time 
PCR system (Thermo Fisher Scientific, Waltham, MA, USA) 
as described previously.26 Briefly, total RNA was extracted 
using Trizol reagent (Sigma-Aldrich Co.) according to the 
manufacturer’s guidelines, and cDNA was synthesized using 
1 µg of RNA with the High-Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher Scientific). SYBR green PCR 
amplification was performed with SensiMix™ SYBR low-ROX 
kit (Bioline, London, UK) using the following primers: iNOS 
(NM_012611.3; 5′-GGA AGA GAC GCA CAG GCA GAG-3′ 
and 5′-GCA GGC ACA CGC AAT GAT GG-3′; product size 
126 bp) and GAPDH (NM_017008.4; 5′-GTT ACC AGG GCT 
GCCTTC TC-3′ and 5′-GGG TTT CCC GTT GAT GAC C-3′; 
product size 168 bp) according to the manufacturer’s guidelines. 
Each sample was analyzed in triplicate in 25 µL reactions. A 
nontemplate control was used as a negative control and included 
in all PCR reactions. Specific products were determined by the 
melting curve analysis as well as agarose gel electrophoresis 
using ethidium bromide. Expression levels between groups were 
compared using the relative comparison method (2-∆∆CT).
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
20
6.
21
2.
8.
95
 o
n 
31
-M
ay
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
6218
asano et al
Statistics
Data are presented as the mean and standard error of the 
mean as described in the text and figure legends. Statistical 
comparisons were made using paired t-tests and one- or two-
way ANOVA with Bonferroni post hoc tests as appropriate. 
A P,0.05 was considered as significant.
Results
ceO2 nanoparticle characterization
Details regarding the characterization of CeO
2
 nanopar-
ticles used in this study have been previously published.15 
SEM and TEM analyses suggested that the particles were 
likely spherical in shape and ∼15–20 nm in diameter 
(Figure 1A and B).
ceO2 nanoparticle treatment improves 
diaphragmatic function in the septic rat
There were significant differences in pre-/post-body weight 
and serum hematocrit levels for the CI and CI+CeO
2
 groups 
but not for the sham and CeO
2
-only treated animals at 
18 hours after the surgery (Table 1). The muscle length at 
which maximal tension was developed (L
o
) was not dif-
ferent between groups (Table 1). Muscle strips from all 
groups demonstrated frequency-dependent increased tension 
(Figure 2A). Peak twitch tension was 93%±5%, 68%±4%, 
and 82%±5% of sham control for CeO
2
 only, CI, and 
CI+CeO
2
, respectively (Table 1; P,0.05). Similarly, peak 
tetanic tension was 89%±3%, 62%±4%, and 78%±4% of 
sham control for CeO
2
 only, CI, and CI+CeO
2
, respectively 
(Figure 2B; P,0.05). Consistent with these data, sepsis 
appeared to increase Procion orange dye diffusion into the 
diaphragm compared with that observed in the other groups 
(Figure 3A). Histological analysis following H&E staining 
suggested that sepsis was associated with increased cell 
infiltration that appeared to be diminished with nanoparticle 
treatment (Figure 3B).
ceO2 nanoparticle treatment attenuates 
sepsis-associated diaphragmatic 
inflammation
Nanoparticle treatment decreased sepsis-induced increases 
in Stat3 phosphorylation at 3- but not 18 hours (Figure 4A; 
P,0.05). Nanoparticle treatment significantly decreased 
iNOS transcript levels and protein in the septic animals 
(Figure 4B and C; P,0.05).
ceO2 nanoparticle treatment suppresses 
translation-related signaling, caspase 8 
cleavage, and protein ubiquination during 
sepsis
Compared with the control animals, the phosphorylation 
of Akt, FOXO-1, and 4EBP-1 was not changed at 3 hours 
(data not shown). Nanoparticle treatment attenuated sepsis-
induced decreases in the phosphorylation of Akt, FOXO-1, 
and 4EBP-1 at 18 hours (Figure 5A–C; P,0.05). Similarly, 
nanoparticle treatment reduced sepsis-associated protein 
ubiquination at 3 hours (Figure 6A; P,0.05) and caspase 8 
cleavage at 18 hours (Figure 6B; P,0.05). Neither sepsis 
nor nanoparticle treatment was associated with changes in 
caspase 3 cleavage, apoptosis-inducing factor, or the ratio 
of Bax/Bcl-2 (data not shown).
Discussion
Previous work from our laboratory using the CI peritonitis 
model has demonstrated that CeO
2
 nanoparticle treatment 
was associated with improved animal survivability and 
6N9PPîN6(8± P QP
$ %
Figure 1 characteristics of cerium oxide (ceO2) nanoparticles.
Notes: Image of ceO2 nanoparticle powder under transmission electron microscopy is shown (A, scale bar =1 µm). ceO2 nanoparticles are further characterized by 
scanning electron microscopy (B, scale bar =20 nm).
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Figure 2 cerium oxide (ceO2) nanoparticle treatment improves diaphragmatic contractility in cecal inoculum (cI) rat.
Notes: representative recording traces of contractile response are shown from each group (A). group data showed that nanoparticle treatment improves diaphragm 
tension development (B, control n=8 strips from 4 rats, ceO2 only n=6 strips from 3 rats, cecal inoculum (cI) n=16 strips from 8 rats and cI+ceO2 n=18 strips from 9 rats). 
*vs control, #vs cI: P,0.05 by two-way repeated measures aNOVa.
Table 1 characteristics of diaphragm strip and animal each group at 18 hours
Sham control CeO2 only CI CI+CeO2
Pre-body weight (g) 419.3±1.9 417.9±8.7 407.3±5.0 409.6±2.8
Post-body weight (g) 425.3±2.1 420.8±8.2 396.1±4.5* 402.1±3.5*
Delta body weight (g) 6.1±1.2 2.9±1.5 -10.0±1.3* -7.6±2.2*
hematocrit (%) 41.3±4.3 46.0±4.0 61.8±3.3* 58.6±1.6*
strip weight (mg) 39.7±3.7 36.2±2.8 39.7±1.7 39.3±1.9
Lo (mm) 20.5±0.4 20.4±0.8 20.0±0.5 19.3±0.3
Pt (N/cm
2) 9.68±0.78 9.04±0.49 6.56±0.34* 7.91±0.48
Po (N/cm
2) 26.45±1.32 23.68±0.80 16.41±1.03* 20.06±1.14**
contraction time (ms) 51.28±2.74 55.53±3.82 49.22±1.74 48.19±2.36
half relaxation time (ms) 50.45±4.00 57.87±4.58 58.65±5.27 50.00±3.14
Notes: *P,0.05 compared with control group. **P,0.05 compared with cI group by one-way aNOVa.
Abbreviations: ceO2, cerium oxide; cl, cecal inoculums; Lo, optimal length; Po, maximal tetanic force; Pt, maximal tetanic force.
diminished systemic inflammation15 with the latter occurring 
most likely due to diminished Kupffer cell activation.21 In this 
study, we show that CeO
2
 nanoparticle treatment attenuates 
the diaphragm dysfunction induced by the septic condition. 
We believe that these are the first data to demonstrate that 
nanoparticle treatments designed to target the liver Kupffer 
cells might be useful for preventing the muscle dysfunc-
tion and atrophy seen in clinical conditions characterized 
by severe systemic inflammation. Similar to earlier studies 
employing other sepsis models,23,29–31 we show that the CI 
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Figure 3 cerium oxide (ceO2) nanoparticle treatment decreases cecal inoculum (cI) induced muscle damage.
Notes: Nanoparticle treatment functions to protect the muscle membrane as suggested by diminished Procion orange signal in the treated animals. Images were obtained using 
an inverted fluorescent microscope with 10× objective lens using a GFP filter (A). Sepsis increases and nanoparticle treatment decreases cellular infiltration. Representative 
bright field images were captured at 20× objective lens (B).
Abbreviations: GFP, green fluorescent protein; H&E, hematoxylin and eosin.
peritonitis model is also characterized by alterations in dia-
phragmatic function (Figure 2). Importantly, we also found 
that the CeO
2
 nanoparticle treatment appeared to diminish 
the effects that the septic condition had on diaphragm ten-
sion development.
Whether these improvements in diaphragm contractil-
ity also reflect an improved pulmonary function in vivo is 
currently unclear. Similarly, why muscle function may be 
decreased with sepsis, or other conditions that are charac-
terized by increased systemic inflammation are not entirely 
understood; however, it has been suggested that increased 
cellular infiltration and/or muscle membrane damage may 
play a role.32 To investigate this possibility, we examined 
the effects of sepsis and nanoparticle treatment on muscle 
histology and membrane permeability following exposure to 
Procion dye. Similar to previous reports,32,33 we found that 
the diaphragms obtained from septic animals exhibited a 
marked increase sarcolemma damage and cellular infiltration 
(Figure 3A). In addition, and consistent with our findings of 
improved contractile function with nanoparticle treatment, 
we found that these changes in cellular structure appeared 
to be lessened with nanoparticle treatment (Figure 3B). To 
extend these data, we next examined if the nanoparticle 
treatment modulated inflammatory signaling in diaphragm. 
Several studies have suggested that elevations in the local 
(muscle) or circulating tumor necrosis factor (TNF)-alpha 
may play a key role in regulating diaphragmatic function 
during infection.16,23,34–37 Our data are consistent with this 
view and previous work from our laboratory that demon-
strated elevations in systemic inflammation in the rat CI 
peritonitis model. How circulating cytokines cause muscle 
contractile dysfunction remains unclear; however, it has 
been shown that the activation of Stat3–iNOS signaling 
by elevations in IL-6 is associated with diminished cardiac 
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Figure 4 cerium oxide (ceO2) nanoparticle treatment attenuates diaphragmatic inflammation after septic insult.
Notes: cecal inoculum (cI) induced increases in stat3 phosphorylation are diminished with nanoparticle treatment (A, n=6 rats/each group). real-time Pcr showed that 
iNOS gene expression levels was increased with cI group and diminished with nanoparticle treatment at 18 hours (B, n=6 rats/each group). Immunoblot for iNOs/α-tubulin 
is shown (C). *vs control, **vs cI: P,0.05 by one-way aNOVa.
Abbreviation: Pcr, polymerase chain reaction.
contractility.38 Similar to the mechanisms of the inflam-
matory response in cardiac muscle, we found that sepsis 
significantly increased Stat3 phosphorylation in diaphragm, 
and importantly, that this increase was attenuated with 
nanoparticle treatment (Figure 4A). Likewise, increases in 
NO have been shown to directly impair contractile function 
in a number of different skeletal muscles including the 
diaphragm.23,30,32,39 Consistent with this premise, we found 
that sepsis significantly increased iNOS gene expression and 
protein content in diaphragm (Figure 4B and C). Similar 
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Figure 5 cerium oxide (ceO2) nanoparticle treatment normalizes the disruption of protein synthesis signaling in cecal inoculum (cI) peritonitis diaphragm.
Notes: effect of nanoparticle on protein synthesis signaling was determined by immunoblot. Nanoparticle treatment increases phospho-akt (A), phospho-Foxo1 (B), and 
phospho-4e-BP1 (C) levels in the septic diaphragm (n=6 rats/each group). *vs control: P,0.05 by one-way aNOVa. **vs cI: P,0.05 by t-test.
to our contractile measurements, these alterations in NO 
signaling were attenuated with nanoparticle treatment. 
Given that CeO
2
 nanoparticles have been shown to possess 
not only redox modulation but also immunomodulation 
properties in vitro,7,8,40 it is possible that our in vivo CeO
2
 
nanoparticle treatment effects may be involved in the regula-
tion of immune function and NO-associated oxidative stress. 
Taken together, these data suggest that nanoparticle treat-
ment attenuated peritonitis-induced diaphragm dysfunction 
and that this improvement in contractility may be associated 
with diminished inflammatory signaling.
CeO2 nanoparticle treatment 
improves protein degradation/
synthesis signaling in the septic 
diaphragm
In addition to muscle damage and increased inflammatory sig-
naling, it is also thought that increases in protein degradation 
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Figure 6 cerium oxide (ceO2) nanoparticle treatment decreases protein ubiquitination and caspase 8 cleavage during sepsis.
Notes: effect of nanoparticle on protein synthesis signaling was determined by immunoblot. sepsis and treatment associated changes in protein ubiquitination (A) and 
caspase 8 cleavage (B). n=6 rats/each group, *vs control: **vs cI: P,0.05 by one-way aNOVa.
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may also be associated with diminished contractile function.41 
It is thought that protein degradation is controlled, at least 
in part, by the activity of the muscle E3 ligases, MURF-1 
and MAFbx, which, in turn, are thought to be regulated 
by FOXO-1. The activity of FOXO-1 is controlled by its 
phosphorylation by Akt, with increased FOXO-1 phospho-
rylation causing a decrease in its transcriptional activity.42 
We found that total FOXO-1 expression was increased in CI 
peritonitis groups (Figure 5B). This finding is in agreement 
with previous reports that suggested that both cecal ligation 
and puncture (CLP)- and lipopolysaccharide (LPS)-induced 
sepsis models are associated with increased skeletal muscle 
FOXO-1 mRNA43,44 and protein levels.45 Conversely, we 
noted that peritonitis was associated with diminished ratio of 
Akt and FOXO-1 phosphorylated (active)/total protein and 
that this ratio that appeared to be attenuated with the treatment 
(Figure 5A and B). These data are consistent with the pos-
sibility that the CeO
2
 nanoparticle intervention might function 
to diminish the degree of sepsis-induced muscle breakdown. 
Why sepsis might increase total FOXO-1 expression is cur-
rently unclear, but it is possible that this change could be a 
compensatory mechanism to counteract sepsis-associated 
decreases in FOXO-1 activity. Further studies will be required 
to address the mechanism(s) responsible for this change, and 
perhaps, more importantly, the physiological relevance of 
why sepsis might affect FOXO-1 protein levels in skeletal 
muscle. In addition to its ability to protect the muscle against 
apoptosis and protein degradation, it is also known that septic 
insults cause decrease protein translation signaling.46,47 To 
investigate this possibility, we next determined the effect of 
sepsis and the nanoparticle intervention on the phosphoryla-
tion of 4EBP-1. It is thought that 4EBP-1 functions to inhibit 
translation by binding to the translation initiation factor elF4E. 
Consistent with previous work from other groups showing 
both endotoxemia and polymicrobial sepsis models decrease 
phosphorylation of 4EBP-1 in rat skeletal muscle,46,47 we 
found that sepsis was associated with decreased phospho-
rylation of 4EBP-1 (Figure 5C). Importantly, we also found 
that the nanoparticle treatment normalized this decreased 
phosphorylation of 4EBP-1 in diaphragm.
Similar to that observed for the effects of protein degra-
dation on muscle function, it is also thought that increased 
muscle apoptosis can also diminish muscle function. Similar 
to previous reports using the LPS endotoxemia model48 
and other work from our laboratory examining the effects 
of sepsis on circulating cytokine levels,15 we also found 
that this model was associated with increased caspase-8 
cleavage (Figure 6B). To determine whether increases in 
caspase-8 cleavage led to increased muscle apoptosis, we 
next examined if peritonitis was associated with increased 
cleavage of caspase-3. Unlike previous data showing that 
LPS challenge increased caspase-3 activity in the rat dia-
phragm, we failed to find any change caspase-3 cleavage or 
caspase-3 activity in CI peritonitis model (data not shown). 
Supporting these data, we also failed to find any change in 
the ratio of Bax/Bcl-2 or in the amount of Apoptosis inducing 
factor (AIF) protein. Why endotoxemia but not the sepsis 
induced by peritonitis may be associated with increased 
caspase-3 activation is currently unclear.
Conclusion
In conclusion, we have demonstrated that CeO
2
 nanoparticle 
treatment attenuated diaphragm dysfunction in a laboratory 
rat model of sepsis. We believe that this may be the first study 
to demonstrate that the systemic delivery of nanoparticles can 
be used to improve muscle function in a preclinical animal 
model of sepsis. How the nanoparticle treatment improved 
diaphragm contractility is currently unclear and will require 
additional experimentation.
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